We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy?
Read MoreHide Full Article
Key Takeaways
UnitedHealth's Q3 earnings jumped 60.6%, while improved margins and lower medical costs fueled recovery.
UNH raised its 2026 EPS outlook to at least $20.50, but membership fell to 48.3 million from 50.1 million.
Optum's margin rose to 5.6%, while UNH's valuation remains below its five-year median.
UnitedHealth Group Incorporated (UNH - Free Report) showed further signs of a turnaround in the third quarter of 2026, with stronger earnings and improving profitability.Earnings beat expectations, medical costs eased, and management raised its annual outlook again. UNH shares jumped 7.4% since then. However, declining membership raises questions about whether the company can sustain its earnings recovery over the long term.
How Strong Was UnitedHealth's Q3?
UNH reported third-quarter adjusted earnings of $4.69 per share,beating the Zacks Consensus Estimate of $4.12 and rising 60.6% year over year.Revenues reached $112.7 billion, exceeding the consensus estimate by 1.2% but slipping from $113.2 billion last year. Operating earnings climbed to $6.6 billion from $4.3 billion, while net margin improved to 3.6% from 2.1%.
The standout number was the medical care ratio, which measures the share of premium revenue spent on medical services. It fell to 88.4% from 89.9% a year ago. Even a modest improvement in this measure can have a large effect on earnings for an insurer of UnitedHealth's size. Lower claims pressure, tighter pricing and redesigned benefits helped drive the change. However, the quarter included $610 million of favorable medical reserve development related to 2026 care. Still, the operating cost ratio also improved to 12.8% from 13.5%, pointing to progress beyond claims alone.
It again raised its 2026 adjusted earnings forecast to at least $20.50 per share from its previous $19.50-$20 range.
Are Better Margins Coming at the Expense of Growth?
That is the central debate after earnings. UnitedHealthcare served 48.3 million people, down from 50.1 million a year ago. Medicare Advantage membership has fallen by 935,000 since the end of 2025 as the company withdrew from less attractive business and adjusted benefits.
The financial payoff: UnitedHealthcare's operating profit increased to $2.8 billion from $1.8 billion despite lower revenue. Its operating margin climbed to 3.3% from 2.1%. Management now expects Medicare Advantage margins near the upper end of its 2-4% target range for 2026.
Executives emphasized dual-eligible and chronic-condition plans alongside higher-value HMOs, rather than chasing enrollment across every product. More than 94% of Medicare-eligible Americans will have access to a UnitedHealthcare Medicare offering next year. A smaller, better-priced book seems healthier than growth that destroys profit. Still, a lasting turnaround requires enrollment to stabilize. Formal 2027 membership guidance remains ahead, making the upcoming selling season an important checkpoint.
Can Optum Sustain Its Recovery?
Optum offers another reason for optimism. Segment operating earnings rose to $3.7 billion from $2.5 billion even as revenue declined to $66.9 billion from $69.2 billion. Its margin expanded to 5.6% from 3.6%.
Optum Health's turnaround was particularly notable. Operating earnings jumped to $735 million from just $41 million last year, with the margin reaching 3.2%. Revenue fell 10% as the business reduced exposure to markets where its value-based care operations lacked scale. Management expects further improvement in Optum Health's profitability in 2027 as it works toward its 6-8% margin target for 2028.
Optum Insight's automation tools and Optum Rx's pharmacy operations offer additional earnings opportunities, but the company still must convert those initiatives into consistent growth. Optum Rx also faces pressure from lower prescription volumes tied to UnitedHealthcare's shrinking membership. Adjusted prescriptions declined to 393 million from 414 million. External customers now account for more than half its covered lives, however, reducing dependence on the insurance business.
Estimate Revisions Are Trending Higher
The Zacks Consensus Estimate for 2026 EPS is now pegged at $20.39, indicating 24.7% year-over-year growth. The earnings estimate has seen eight upward revisions over the past week against no downward movement. The consensus estimate for revenues is pegged at $447.4 billion, implying only a marginal decline from a year ago.
For 2027, EPS is now projected to grow to $22.99, marking a 12.8% improvement. It has also seen seven upward estimate revisions in the past week, against no cuts. Revenues are pegged at $460.01 billion, indicating 2.8% growth from a year ago.
The company beat earnings estimates in each of the past four quarters, producing an average earnings surprise of 14%.
Medical utilization remains the biggest uncertainty. Management said that commercial medical cost trends remain above 11%, although they have stabilized recently. Management expects core Medicaid margins to remain negative but better than negative 1% in 2026, with improvement anticipated in 2027.
Medicare Advantage quality ratings add another challenge. For 2027, at least 69% of UnitedHealthcare's Medicare Advantage members are in plans rated four stars or higher, down from approximately 78% for 2026, per reports.Lower ratings can weigh on future bonus payments and product competitiveness. Nevertheless, UnitedHealth is targeting approximately 75% for 2028.
Cash generation and debt also deserve attention. Operating cash flow totaled $5.1 billion in the quarter, or 1.2 times net income. Debt represented 41.7% of capital at September's end. The company aims to approach 40% by year-end while funding investments, dividends and repurchases.
YTD Price Performance
Looking at the year-to-date period, UNH stock has gained 23.2%, outperforming the S&P 500’s 12.9% rise, but trailing the industry’s 26% growth. Peers like Molina Healthcare, Inc. (MOH - Free Report) and Centene Corporation (CNC - Free Report) have increased 22.5% and 71.4%, respectively, during this time.
Price Performance – UNH, MOH, CNC, Industry & S&P 500
Image Source: Zacks Investment Research
Valuation Still Below Historical Levels
UNH trades at 18.50X forward earnings, above the industry average of 16.08X but below its five-year median of 19.02X. In comparison, Molina and Centene are currently priced at 24.07X and 13.44X, respectively, both higher than their own five-year median multiples.
Image Source: Zacks Investment Research
Wall Street also sees room for further gains. Despite the stock’s recent rise, the average analyst price target of $476.52 suggests an upside of 17.2% from current levels. Individual targets range from $380 to $529, indicating that analysts remain divided over the pace and extent of UnitedHealth's recovery.
Is UNH Stock Worth Buying Now?
UnitedHealth's stronger third-quarter earnings, improving margins and raised guidance suggest that its turnaround is moving in the right direction. Upward earnings estimate revisions add to the positive outlook. Although declining membership, elevated utilization and Medicare Advantage rating pressures remain concerns, management’s focus on profitable growth should help strengthen results over time.
UNH's valuation remains below its historical median, while Optum's improving profitability provides another reason for optimism. Despite continued pressure from membership losses and elevated medical cost trends, the stock carries a Zacks Rank #2 (Buy), making it an attractive option for investors looking to benefit from the company's turnaround. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
View the Zacks #1 Rank List
Image: Bigstock
UnitedHealth's Q3 Margins Improve, But Membership Falls: Time to Buy?
Key Takeaways
UnitedHealth Group Incorporated (UNH - Free Report) showed further signs of a turnaround in the third quarter of 2026, with stronger earnings and improving profitability.Earnings beat expectations, medical costs eased, and management raised its annual outlook again. UNH shares jumped 7.4% since then. However, declining membership raises questions about whether the company can sustain its earnings recovery over the long term.
How Strong Was UnitedHealth's Q3?
UNH reported third-quarter adjusted earnings of $4.69 per share,beating the Zacks Consensus Estimate of $4.12 and rising 60.6% year over year.Revenues reached $112.7 billion, exceeding the consensus estimate by 1.2% but slipping from $113.2 billion last year. Operating earnings climbed to $6.6 billion from $4.3 billion, while net margin improved to 3.6% from 2.1%.
The standout number was the medical care ratio, which measures the share of premium revenue spent on medical services. It fell to 88.4% from 89.9% a year ago. Even a modest improvement in this measure can have a large effect on earnings for an insurer of UnitedHealth's size. Lower claims pressure, tighter pricing and redesigned benefits helped drive the change. However, the quarter included $610 million of favorable medical reserve development related to 2026 care. Still, the operating cost ratio also improved to 12.8% from 13.5%, pointing to progress beyond claims alone.
It again raised its 2026 adjusted earnings forecast to at least $20.50 per share from its previous $19.50-$20 range.
For further details, see UNH Tops Q3 Earnings on Lower Medical Costs, Raises '26 Outlook.
Are Better Margins Coming at the Expense of Growth?
That is the central debate after earnings. UnitedHealthcare served 48.3 million people, down from 50.1 million a year ago. Medicare Advantage membership has fallen by 935,000 since the end of 2025 as the company withdrew from less attractive business and adjusted benefits.
The financial payoff: UnitedHealthcare's operating profit increased to $2.8 billion from $1.8 billion despite lower revenue. Its operating margin climbed to 3.3% from 2.1%. Management now expects Medicare Advantage margins near the upper end of its 2-4% target range for 2026.
Executives emphasized dual-eligible and chronic-condition plans alongside higher-value HMOs, rather than chasing enrollment across every product. More than 94% of Medicare-eligible Americans will have access to a UnitedHealthcare Medicare offering next year. A smaller, better-priced book seems healthier than growth that destroys profit. Still, a lasting turnaround requires enrollment to stabilize. Formal 2027 membership guidance remains ahead, making the upcoming selling season an important checkpoint.
Can Optum Sustain Its Recovery?
Optum offers another reason for optimism. Segment operating earnings rose to $3.7 billion from $2.5 billion even as revenue declined to $66.9 billion from $69.2 billion. Its margin expanded to 5.6% from 3.6%.
Optum Health's turnaround was particularly notable. Operating earnings jumped to $735 million from just $41 million last year, with the margin reaching 3.2%. Revenue fell 10% as the business reduced exposure to markets where its value-based care operations lacked scale. Management expects further improvement in Optum Health's profitability in 2027 as it works toward its 6-8% margin target for 2028.
Optum Insight's automation tools and Optum Rx's pharmacy operations offer additional earnings opportunities, but the company still must convert those initiatives into consistent growth. Optum Rx also faces pressure from lower prescription volumes tied to UnitedHealthcare's shrinking membership. Adjusted prescriptions declined to 393 million from 414 million. External customers now account for more than half its covered lives, however, reducing dependence on the insurance business.
Estimate Revisions Are Trending Higher
The Zacks Consensus Estimate for 2026 EPS is now pegged at $20.39, indicating 24.7% year-over-year growth. The earnings estimate has seen eight upward revisions over the past week against no downward movement. The consensus estimate for revenues is pegged at $447.4 billion, implying only a marginal decline from a year ago.
For 2027, EPS is now projected to grow to $22.99, marking a 12.8% improvement. It has also seen seven upward estimate revisions in the past week, against no cuts. Revenues are pegged at $460.01 billion, indicating 2.8% growth from a year ago.
The company beat earnings estimates in each of the past four quarters, producing an average earnings surprise of 14%.
UnitedHealth Price, Consensus and EPS Surprise
UnitedHealth Group Incorporated price-consensus-eps-surprise-chart | UnitedHealth Group Incorporated Quote
What Could Disrupt the Recovery?
Medical utilization remains the biggest uncertainty. Management said that commercial medical cost trends remain above 11%, although they have stabilized recently. Management expects core Medicaid margins to remain negative but better than negative 1% in 2026, with improvement anticipated in 2027.
Medicare Advantage quality ratings add another challenge. For 2027, at least 69% of UnitedHealthcare's Medicare Advantage members are in plans rated four stars or higher, down from approximately 78% for 2026, per reports.Lower ratings can weigh on future bonus payments and product competitiveness. Nevertheless, UnitedHealth is targeting approximately 75% for 2028.
Cash generation and debt also deserve attention. Operating cash flow totaled $5.1 billion in the quarter, or 1.2 times net income. Debt represented 41.7% of capital at September's end. The company aims to approach 40% by year-end while funding investments, dividends and repurchases.
YTD Price Performance
Looking at the year-to-date period, UNH stock has gained 23.2%, outperforming the S&P 500’s 12.9% rise, but trailing the industry’s 26% growth. Peers like Molina Healthcare, Inc. (MOH - Free Report) and Centene Corporation (CNC - Free Report) have increased 22.5% and 71.4%, respectively, during this time.
Price Performance – UNH, MOH, CNC, Industry & S&P 500
Valuation Still Below Historical Levels
UNH trades at 18.50X forward earnings, above the industry average of 16.08X but below its five-year median of 19.02X. In comparison, Molina and Centene are currently priced at 24.07X and 13.44X, respectively, both higher than their own five-year median multiples.
Wall Street also sees room for further gains. Despite the stock’s recent rise, the average analyst price target of $476.52 suggests an upside of 17.2% from current levels. Individual targets range from $380 to $529, indicating that analysts remain divided over the pace and extent of UnitedHealth's recovery.
Is UNH Stock Worth Buying Now?
UnitedHealth's stronger third-quarter earnings, improving margins and raised guidance suggest that its turnaround is moving in the right direction. Upward earnings estimate revisions add to the positive outlook. Although declining membership, elevated utilization and Medicare Advantage rating pressures remain concerns, management’s focus on profitable growth should help strengthen results over time.
UNH's valuation remains below its historical median, while Optum's improving profitability provides another reason for optimism. Despite continued pressure from membership losses and elevated medical cost trends, the stock carries a Zacks Rank #2 (Buy), making it an attractive option for investors looking to benefit from the company's turnaround. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.